^
Association details:
| Biomarker: | KMT2A rearrangement |
|---|---|
| Cancer: | Childhood B Acute Lymphoblastic Leukemia |
| Drug: | Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia
Published date:
04/27/2023
Excerpt:
Blinatumomab added to Interfant-06 chemotherapy appeared to be safe and had a high level of efficacy in infants with newly diagnosed KMT2A-rearranged ALL as compared with historical controls from the Interfant-06 trial.
Secondary therapy:
Chemotherapy
DOI:
10.1056/NEJMoa2214171
Trial ID:
Source:
Title:
361 A Phase 2 Study to Test the Feasibility, Safety and Efficacy of the Addition of Blinatumomab to the Interfant06 Backbone in Infants with Newly Diagnosed KMT2A-Rearranged Acute Lymphoblastic Leukemia. a Collaborative Study of the Interfant Network
Published date:
11/04/2021
Excerpt:
Twenty-eight patients were enrolled. Baseline characteristics are shown in Table 1. The median follow-up was 11 months (range 1.5-33 months). All patients received the full course of blinatumomab without treatment interruptions….The 1-year EFS was 96.2% (SE 3.8)....This is the first trial to use blinatumomab in infants with newly diagnosed KMT2A-r ALL. Blinatumomab added to the Interfant06 backbone was very well tolerated, and has promising efficacy in terms of a high rate of complete MRD response and short term EFS.
